Interactive Investor

Market snapshot: vaccine progress and Tesco repays Covid aid

2nd December 2020 08:15

Richard Hunter from interactive investor

Loading

Share on

November's optimism has spilled over into December in what is traditionally a strong period for stocks.

A raft of positive news has led to further investor optimism and a strong start to December.

In the US, talks of a much anticipated fiscal stimulus package appear to be back on the table at a time when the economy is still stuttering under the effects of the pandemic. Hopes for a further injection aimed at accelerating the recovery tempted back the bulls. M&A activity also provided a further boost as a $28 billion deal between Salesforce.com (NYSE:CRM) and Slack Technologies (NYSE:WORK) followed hot on the heels of the $44 billion S&P Global/IHS Markit acquisition announced the previous day.

More broadly, there was also progress on the Covid-19 vaccine, with both Pfizer (NYSE:PFE) and its German partner BioNTech (NASDAQ:BNTX) as well as Moderna (NASDAQ:MRNA) confirming that emergency approval had been sought in Europe. Indeed, this has now been granted for the Pfizer/BioNTech vaccine in the UK, with a targeted roll out potentially beginning as early as next week.

These combined fillips to sentiment drove both the S&P 500 and the Nasdaq to record closing highs, with the indices now having risen by 13.3% and 37.6% respectively in the year to date, and with the Dow Jones not far behind, and ahead by 4.5% in 2020.

In addition to the vaccine developments, the FTSE 100 was also buoyed by some comforting factory activity and confidence data, even though it appears that Brexit negotiations are going to the wire. 

The FTSE remains down by 15.3% in the year to date, but the positive November momentum which spilled over to the first trading day of December is a possible sign of a turn in the tide of sentiment towards the UK’s flagship index.

Tesco (LSE:TSCO) provided a somewhat surprising announcement that it would be returning the £585 million of business rates relief which it has received to date, despite incurring estimated Covid-19 related costs of £725 million thus far. This action may also throw down the gauntlet to some of its blue chip rivals, resulting in some other companies potentially following suit.

These articles are provided for information purposes only.  Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties.  The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.

Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.

Get more news and expert articles direct to your inbox

Sign up for a free research account to get the latest news and discussion, and create your own virtual portfolio.

Free Sign Up